Tracey, Brian
Volfson, Dmitri
Glass, James
Haulcy, R’mani
Kostrzebski, Melissa
Adams, Jamie
Kangarloo, Tairmae
Brodtmann, Amy
Dorsey, E. Ray
Vogel, Adam
Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A.
Biogen
members of the Critical Path for Parkinson’s Consortium 3DT Initiative, Stage 2
Article History
Received: 14 January 2023
Accepted: 7 December 2023
First Online: 21 December 2023
Competing interests
: B. Tracey, D. Volfson and T. Kangarloo are full-time employees of and own stock in Takeda Pharmaceuticals. M. Kostrzebski holds stock in Apple, Inc. J. Adams has received compensation for consulting services from VisualDx and the Huntington Study Group; and research support from Biogen, Biosensics, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health/National Institute of Neurological Disorders and Stroke, NeuroNext Network, and Safra Foundation. E. Dorsey has received compensation for consulting services from Abbott, Abbvie, Acadia, Acorda, Bial-Biotech Investments, Inc., Biogen, Boehringer Ingelheim, California Pacific Medical Center, Caraway Therapeutics, Curasen Therapeutics, Denali Therapeutics, Eli Lilly, Genentech/Roche, Grand Rounds, Huntington Study Group, Informa Pharma Consulting, Karger Publications, LifeSciences Consultants, MCM Education, Mediflix, Medopad, Medrhythms, Merck, Michael J. Fox Foundation, NACCME, Neurocrine, NeuroDerm, NIH, Novartis, Origent Data Sciences, Otsuka, Physician’s Education Resource, Praxis, PRIME Education, Roach, Brown, McCarthy and Gruber, Sanofi, Seminal Healthcare, Spark, Springer Healthcare, Sunovion Pharma, Theravance, Voyager and WebMD; research support from Biosensics, Burroughs Wellcome Fund, CuraSen, Greater Rochester Health Foundation, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health, Patient-Centered Outcomes Research Institute, Pfizer, PhotoPharmics, Safra Foundation, and Wave Life Sciences; editorial services for Karger Publications; stock in Included Health and in Mediflix, and ownership interests in SemCap. J. Glass and R. Haulcy have received research funding from Takeda Pharmaceuticals. A.Vogel is Chief Science Officer of Redenlab P/L who undertake speech biomarker research services. A. Brodtmann has no competing financial interests.